Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus–coinfected patients
✍ Scribed by Juan Macías; Juan Berenguer; Miguel A. Japón; José A. Girón-González; Antonio Rivero; Luis F. López-Cortés; Ana Moreno; Manuel Márquez; José A. Iribarren; Enrique Ortega; Pilar Miralles; Nicolás Merchante; Juan A. Pineda
- Book ID
- 115556288
- Publisher
- John Wiley and Sons
- Year
- 2012
- Tongue
- English
- Weight
- 468 KB
- Volume
- 56
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Hepatic steatosis (HS) is frequent in patients with hepatitis C virus (HCV) infection, occurring in 40%-80%, associating with metabolic and virus-related factors, namely, genotype 3 and viral load. Human immunodeficiency virus (HIV) infection and antiretroviral treatment seem to be risk factors for
## Abstract The aim of this study was to examine whether hepatitis C virus (HCV) pretreatment quasispecies complexity was linked to virological response or other clinical and biological parameters, in human immunodeficiency virus (HIV)‐coinfected patients undergoing anti‐HCV treatment. In addition,
Hepatic steatosis has been reported in human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfection. However, the features of steatohepatitis, including cytologic ballooning and pericellular fibrosis, its risk factors, and the impact on disease severity in such patients are unknown. To ass